Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors

NCT00069277 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: E7389

Sponsor

Eisai Inc.